Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q4 2019 · 10-K
Revenue$106.87M$106.87M+39.7% vs Q4 2018 Net Income$6.30M$6.30M+1,683.6% vs Q4 2018 EPS Diluted$0.06$0.06— vs Q4 2018 Gross Profit$49,923,000+34.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$3,359,000−78.3% Free Cash Flowderived-$2,717,000N/M Margins · derivedGross margin46.7%−1.8 pt vs Q4 2018
Operating margin2.2%−1.5 pt vs Q4 2018
Net margin5.9%+5.4 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 28, 2020 · 59 d after period end